Summary
The immunohistochemical expression of the aspartyl protease enzyme cathepsin D was examined in a consecutive series of 103 primary operable breast carcinomas with the polyclonal antibody NCL-CDp. Expression of cathepsin D was identified within the epithelial and stromal components of all tumours examined. No significant associations of increased cathepsin D expression in the epithelial tumour component with conventional prognostic indices such as tumour size, grade, lymph node stage, or patient survival were identified. However, significant associations of increased stromal cathepsin D expression and high tumour grade,χ 2 = 11.40 (df = 2), p = 0.003; increased tendency to local recurrence,χ 2 = 6.87 (df = 1), p = 0.009; regional recurrence,χ 2 = 7.44 (df = 1), p = 0.006; poorer disease free survival,χ 2 = 14.9 (df = 1), p = 0.0001; and poorer overall patient survival,χ 2 = 6.90 (df = 1), p = 0.0086, were identified. Cathepsin D expression is present in all breast tumours. Stromal cathepsin D expression is a neglected immunohistochemical prognostic parameter which could explain some of the previous apparently conflicting reports concerning the effect on patient prognosis of biochemical (i.e. total) and immunohistochemical estimations of cathepsin D in breast cancers.
References
Press EM, Porter RR, Cebra J: The isolation and properties of a proteolytic enzyme, cathepsin D, from bovine spleen. Biochem J 74: 501–504, 1960
Abecassis J, Collard R, Eber Met al.: Proteinases and sialyltransferase in human breast tumors. Int J Cancer 33: 821–824, 1984
Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H:In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 48: 3688–3692, 1988
Brouillet JP, Theillet C, Maudelonde Tet al.: Cathepsin D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erbB-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer 26: 437–441, 1990
Capony F, Rougeot C, Montcourrier Pet al.: Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res 49: 3904–3909, 1989
Duffy MJ, Brouillet JP, Reilly Det al.: Cathepsin D concentration in breast cancer cytosols: Correlation with biochemical, histological, and clinical findings. Clin Chem 37: 101–104, 1991
Foucre D, Bouchet C, Hacene Ket al.: Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignantvs benign breast tumours. Br J Cancer 64: 926–932, 1991
Granata G, Coradini D, Cappelletti V, Di Fronzo G: Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 27: 970–972, 1991
Henry JA, McCarthy AL, Angus Bet al.: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 65: 265–271, 1990
Levy J, Kolski GB, Douglas SD: Cathepsin D-like activity in neutrophils and monocytes. Infection Immun 57: 1632–1634, 1989
Maguchi S, Taniguchi N, Makita A: Elevated activity and increased mannose-6-phosphate in the carbohydrate moiety of cathepsin D from human hepatoma. Cancer Res 48: 362–367, 1988
Maudelonde T, Khalaf S, Garcia Met al.: Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: Low correlation with other prognostic parameters. Cancer Res 48: 462–466, 1988
Maudelonde T, Domergue J, Henquel Cet al.: Tamoxifen treatment increases the concentration of 52 K cathepsin D and its precursor in breast cancer tissue. Cancer 63: 1265–1270, 1989
Maudelonde T, Martinez P, Brouillet JPet al.: Cathepsin D in human endometrium: Induction by progesterone and potential value as a tumor marker. J Clin Endocrinol Metab 70: 115–121, 1990
Montcourrier P, Mangeat PH, Salazar G: Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res 50: 6045–6054, 1990
Parham D, Whitaker JN, Berard CW: Cellular distribution of cathepsin D in childhood tumors. Arch Pathol Lab Med 109: 250–255, 1985
Poole AR, Dingle JT, Barrett AJ: The immunocytochemical demonstration of cathepsin D. J Histochem Cytochem 20: 261–265, 1972
Reid WA, Valler MJ, Kay J: Immunolocalisation of cathepsin D in normal and neoplastic human tissues. J Clin Pathol 39: 1323–1330, 1986
Rochefort H, Cavailles V, Augereau Pet al.: Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem 34: 177–182, 1989
Saku T, Sakai H, Tsuda Net al.: Cathepsins D and E in normal, metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study. Gut 31: 1250–1255, 1990
Scambia G, Panici PB, Ferrandina Get al.: Cathepsin D and epidermal growth factor in human breast cyst fluid. Br J Cancer 64: 965–967, 1991
Scambia G, Benedetti P, Ferrandina Get al.: Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone, and epidermal growth factor. Br J Cancer 64: 182–184, 1991
Spyratos F, Maudelonde T, Brouillet JPet al.: Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet ii: 1115–1118, 1989
Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302, 1990
Thorpe SM, Rochefort H, Garcia Met al.: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008–6014, 1989
Garcia M, Salazar-Retana G, Pages Aet al.: Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. Cancer Res 46: 3734–3738, 1986
Remmele W, Manthey JS: Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Archiv (A) 422: 467–473, 1993
Tetu B, Brisson J, Cote C, Brisson S, Potvin D, Roberge N: Prognostic significance of cathepsin D expression in nodepositive breast carcinoma: An immunohistochemical study. Int J Cancer 55: 429–435, 1993
Kandalaft PL, Chang KL, Ahn CW, Traweek ST, Mehta P, Battifora H: Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer 71: 2756–2763, 1993
Rogers S, Day CA, Fox SB: Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol 24: 148–151, 1993
Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M: Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. Am J Pathol 141: 1003–1012, 1992
Isola J, Weitz S, Visakorpi Tet al.: Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 11: 36–43, 1993
Winstanley JH, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS: Prognostic significance of cathepsin D in patients with breast cancer. Br J Cancer 67: 767–772, 1993
Armas OA, Gerald WL, Lesser ML, Arroyo CD, Norton L, Rosen PP: Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol 18: 158–166, 1994
Charpin C, Bonnier P, Khouzami Aet al.: Inflammatory breast carcinoma: An immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 12: 591–597, 1992
Kominami E, Ueno T, Muno D, Katunuma N: The selective role of cathepsins B and D in the lysosomal degradation of endogenous and exogenous proteins. FEBS Lett 287: 189–192, 1991
Diment S, Leech MS, Stahl PD: Cathepsin D is membraneassociated in macrophage endosomes. J Biol Chem 263: 6901–6907, 1988
Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56: 489–492, 1987
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410, 1991
Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW: Pathological prognostic factors in breast cancer II. Histological type. Relationship with survival in a large study with long term follow-up. Histopathology 20: 479–489, 1992
Briozo P, Badet J, Capony Fet al.: MCF 7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: A permissive role of cathepsin D. Exp Cell Res 194: 252–259, 1991
Hansen JG, Ralfkiaer E, Kirkeby LTet al.: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138: 111–117, 1991
Garcia M, Derocq D, Pujol P, Rochefort H: Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5: 1809–1814, 1990
Cavailles V, Augereau P, Rochefort H: Cathepsin D gene of human MCF 7 cells contains estrogen-responsive sequences in its 5′ proximal flanking region. Biochem Biophys Res Commun 174: 816–824, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Donoghue, A.E.M.A., Poller, D.N., Bell, J.A. et al. Cathepsin D in primary breast carcinoma: Adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Tr 33, 137–145 (1995). https://doi.org/10.1007/BF00682721
Issue Date:
DOI: https://doi.org/10.1007/BF00682721